Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CME GroupCME +0.54%84 3-Year EPS without NRI Growth Rate is 12.00% as of Jun. 2026, which is 11% below its 10-year median of 13.50. GuruFocus rates CME with a GF Score™ of 84/100 and a GF Value™ of $272.85 (Fairly Valued). The stock has 3 warning signs investors should review. Among 581 Capital Markets companies, CME Group ranks worse than 54.91% on this metric.
During the past 12 months, CME Group's average EPS without NRI Growth Rate was 7.70% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 12.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 12.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 10.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of CME Group was 45.70% per year. The lowest was -14.90% per year. And the median was 13.50% per year.
CME Group (NAS:CME) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
CME Group 3-Year EPS without NRI Growth Rate Related Terms
CME vs ICE, MCO, SPGI: 3-Year EPS without NRI Growth Rate Comparison
For the Financial Data & Stock Exchanges subindustry, CME Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CME Group 3-Year EPS without NRI Growth Rate vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CME Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CME Group's 3-Year EPS without NRI Growth Rate falls into.
CME Group 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 12.00% mean?
CME Group (CME) has a 3-Year EPS without NRI Growth Rate of 12.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CME Group and its competitors. This is 11% below median its historical median of 13.50. According to the industry distribution chart, CME Group ranks #319 out of 581 companies in the Capital Markets industry, placing it in the top 54.9%.
Is CME Group's 3-Year EPS without NRI Growth Rate too high?
CME Group's current 3-Year EPS without NRI Growth Rate of 12.00% is 11% below median its 10-year median of 13.50. The Capital Markets industry median 3-Year EPS without NRI Growth Rate is 15.50. CME Group's value of 12.00% is 22.6% below this industry median. Based on the distribution chart, CME Group ranks #319 out of 581 companies in the Capital Markets industry, which is below the industry midpoint. Overall, CME Group has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CME Group's 3-Year EPS without NRI Growth Rate compare to ICE and MCO?
According to the Capital Markets industry distribution chart, CME Group ranks #319 out of 581 companies for 3-Year EPS without NRI Growth Rate. This places CME Group in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.50. CME Group's value of 12.00% is 22.6% below this benchmark. While the company's 10-year median is 13.50 vs. the industry median of 15.50, CME Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Capital Markets company?
The median 3-Year EPS without NRI Growth Rate among Capital Markets companies is 15.50, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CME Group's current 3-Year EPS without NRI Growth Rate of 12.00% is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CME Group and its competitors. For the Capital Markets industry, the median 3-Year EPS without NRI Growth Rate is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CME Group's current 3-Year EPS without NRI Growth Rate is 12.00%, which is 11% below median its own 10-year median of 13.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CME Group stock overvalued right now?
Based on GuruFocus' analysis, CME Group (CME) is currently considered Fairly Valued. The stock's GF Value™ is $272.85, compared to a current price of $275.54 — trading 1% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 12.00%, which is 11% below median its 10-year median of 13.50 and 22.6% below the Capital Markets industry median of 15.50. CME Group's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For CME Group (CME), the current 3-Year EPS without NRI Growth Rate is 12.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CME Group (CME) Overvalued in 2026?
Based on GuruFocus' analysis, CME Group stock appears to be overvalued.
The current stock price of $275.54 is trading 1% above its estimated GF Value™ of $272.85.
GuruFocus considers CME Group to be Fairly Valued.
Key valuation signals for CME:
3-Year EPS without NRI Growth Rate: 12.00% (11% below median its 10-year median of 13.50)
GF Value™: $272.85 vs. price of $275.54 (1% above fair value)
Industry Position: 22.6% below the Capital Markets median (#319 of 581)
No single metric tells the full story. See the CME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
84GF Score
Get the complete analysis for CME
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CME has been successfully added to your 
